Fresh Equities



BOTANIX PHARMACEUTICALS LTD has not announced any current capital raises, but we are collecting interest for future raises.

Demand Registered for Next Raise
< $50k
Investors Interested in Next Raise
< 10
How Fresh Equities Works

1. Create Account

Complete your onboarding digitally in less than 3 minutes.


2. View Terms

View the full term sheet for the capital raise.


3. Bid for Allocation

Submit and track your bid online.

Capital Raise History


Company Overview

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.


Listed Company

GICS Sub-industry


Head Office

68 Aberdeen St, Northbridge WA 6003, Australia

Health Care
Biotech & Health

Price Chart

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.




All Time
    Final Director's Interest Notice RT on 11 February 2020

    Shareholder Details

    Initial Director's Interest Notice MC on 11 February 2020

    Shareholder Details

    Botanix Board Update on 10 February 2020

    Company Administration

  • Appendix 4C - Quarterly on 30 January 2020

    Commitments test entity quarterly reports

  • Botanix receives A$7.6m R&D Tax Incentive refund on 28 January 2020

    Periodic Reports

    Botanix Attends USA Healthcare Conferences on 12 January 2020

    Progress Report

    Change of Director's Interest Notice RT on 22 December 2019

    Shareholder Details

    Change in substantial holding on 16 December 2019

    Shareholder Details

    Interview Botanix Corporate Update on 16 December 2019

    Progress Report

    Change of Director's Interest Notice MT on 10 December 2019

    Shareholder Details

    Load More


Fresh Equities does not have BOTANIX PHARMACEUTICALS LTD news data.